I Ask This Of You!

I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.

I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.

I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.

This is for you to read and to always keep an open mind.

Please discuss this with your doctor, should you have any questions, or concerns.

Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.

This is a free site for all with no advertisements.

Thank you for visiting!

Monday, May 29, 2017

Brandon Capital on board as Parkinson's smartwatch firm Global Kinetics seeks $30 million

May 29, 2017

Global Kinetics chief executive Tim Still wearing the company's PKG device.

Emerging Australian medtech success story Global Kinetics is raising $20-30 million to keep commercialising its smartwatch-style Parkinson's treatment device.
The company is also working on an expansion into telehealth in partnership with French hospitals and developing an app to give Parkinson's patients more control over their own treatment.
The latest capital raise follows a $14.8 million round in June 2015 and already has interest from Brandon Capital, which participated in its previous raise, and is planning to take a significant position through its Medical Research Commercialisation Funds.
"Global Kinetics continues to make impressive progress on the commercialisation of its novel device, the PKG, as recognised by its recent ranking as one of the top 10 health companies in the US by Fast Company ... we remain excited about the company's future," Brandon Capital managing director Chris Nave said.
Global Kinetics' Parkinson's KinetiGraph devices continuously record the movement symptoms of a Parkinson's sufferers including bradykinesia, dyskinesia and tremors, the relationship between these symptoms, the timing medication is taken, and the amount of exercise and sleep the person is getting.
The devices are currently being used in more than 200 movement-disorder clinics across 13 countries such as the US, UK, Sweden and Australia.

Clinical practices

Mr Still said there were applications for its technology with other diseases, but Parkinson's remained the focus for now.
"There's an opportunity to go into Huntington's, but it's not a big market. We have also started to do some work in ADHD. But we still feel there's quite a bit of opportunity just with Parkinson's," he said.
The company was founded in Melbourne in 2007 by a team at the Florey Institute led by Professor Malcolm Horne.
It started out as two algorithms which measured bradykinesia and dyskinesia and produced a score for both types of movements every two minutes, based on sensors placed on the limbs of Parkinson's sufferers. These algorithms were then developed into a system that could be used in clinical practices by Global Kinetics.
Now, Global Kinetics has delivered over 16,000 reports to clinicians, based on the movement symptoms dedicated by its PKG devices.
In addition to providing the PKG through clinics, Global Kinetics head of business development Michelle Goldsmith said the company wanted to give patients more control by developing an app called myPKG, which will in part be funded by the new capital raise.
"It's about empowering a person with Parkinson's to be the expert on their own disease. The key thing is medication compliance and taking it on time, consumption of water and amount of exercise," she said.

No comments:

Post a Comment